(109) Target-mediated drug disposition modeling of nonlinear pharmacokinetics in GLP-1 receptor agonists

Semaglutide and liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity. Despite their shared mechanism of action, they exhibit distinct pharmacokinetic profiles. Target-mediated drug disposition (TMDD) occurs when a drug binds with high affinity to a specific receptor, leading to nonlinear pharmacokinetics. This study aimed to develop a TMDD model to describe and compare the pharmacokinetic characteristics of semaglutide and liraglutide.